Goldman Sachs initiated coverage of Summit Therapeutics (SMMT) with a Buy rating and $42 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- Biotech Alert: Searches spiking for these stocks today
- Summit Therapeutics’ Earnings Call Highlights: Collaborations and Clinical Progress
- Positive Outlook for Summit Therapeutics: Strategic Collaborations and Promising Trials Justify Buy Rating
- Buy Rating for Summit Therapeutics Driven by Strategic Pfizer Collaboration and Promising Clinical Trial Readouts
- Summit Therapeutics: Strong Financials and Strategic Collaborations Drive Buy Rating